Jcr Pharmaceuticals Co., Ltd. (4552) Press Release
FY2026 First Quarter Results Briefing Session Material
Earlier from Jcr Pharmaceuticals
- JCR Pharmaceuticals - Notice Regarding the Completion of Payment for the Disposition of Treasury Stock as Restricted Stock Compensation
- JCR Pharmaceuticals Receives Marketing Authorization in the United Arab Emirates for IZCARGO™, a Blood-Brain Barrier-Penetrating Enzyme Replacement Therapy for Hunter Syndrome
- JCR Pharmaceuticals Announces Development Plan in Japan for Givinostat for Duchenne Muscular Dystrophy
- Matters Concerning Controlling Shareholders (Affiliated Companies)